Myelodysplastic Syndrome Related to the Use of Etanercept in a Patient with Psoriasis Vulgaris

Abstract

Keywords

psoriasis hematologic myelodysplastic syndrome treatment

Get full access to this article

View all access options for this article.

References

Nair

, Raval

, Mehta

Tnf-alpha inhibitor etanercept and hematologic malignancies: report of a case and review of the literature. Am J Hematol. 2007; 82: 1022–4.

Rosenfeld

C.S.

, Bedell

Pilot study of recombinant human soluble tumor necrosis factor receptor (TNFR: Fc) in patients with low risk myelodysplastic syndrome. Leuk Res. 2002; 26: 721–4.

Chen

, Holland

M.J.

, Mir

M.R.

Frequency of thrombocytopenia in psoriasis patients treated with tumor necrosis factor-α inhibitors. J Drugs Dermatol. 2011; 10: 280–4.

Liu

Y.C.

, Ito

, Hsiao

H.H.

Risk factor analysis in myelodysplastic syndrome patients with del(20q): prognosis revisited. Cancer Genet Cytogenet. 2006; 171: 9–16.

Warlick

E.D.

, Smith

B.D.

Myelodysplastic syndromes: review of pathophysiology and current novel treatment approaches. Curr Cancer Drug Targets. 2007; 7: 541–58.